A U.S. company acquiring a Chinese company will face a multitude of regulatory restrictions and requirements. How can the U.S. acquirer manage the risk of the deal being blocked or unwound for non-compliance?
CFIUS publishes data from 2021; Autonomous vehicles can be driven in simple and controlled conditions; Trust firms' loans to real estate sector audited
Foreign investors have the same shareholding cap as domestic investors in insurance asset management companies. CSRC sets forth disclosure requirements for listed pharma companies. Land approval procedures for infrastructure projects are streamlined.
Nate Bush and Della Ding of DLA Piper and Ray Xu of Shanghai Kaiman Law Firm assess the implications for dominant firms of recent amendments to China's key anti-monopoly legislation and proposed revisions to its implementing rules.
Research casts doubt on US-listed Chinese companies' ability to list in Hong Kong; Grocery delivery company in legal trouble following collapse; new rules on convertible bonds
CBIRC allows multinationals to set up their own group finance companies and enriches the life insurance disclosure requirements of insurance companies. CNIPA enhances IP protection of exhibitions.
